$DNTH
Dianthus Therapeutics, Inc. /DE/

2022 Q3 Form 10-Q Financial Statement

#000119312522211881 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.052M $6.480M $7.287M
YoY Change -18.77% -0.02% 4.55%
% of Gross Profit
Research & Development $11.20M $11.60M $16.55M
YoY Change 3.76% 4.26% 41.07%
% of Gross Profit
Depreciation & Amortization $471.0K $477.0K $511.0K
YoY Change -11.47% -1.24% 8.72%
% of Gross Profit
Operating Expenses $17.25M $18.08M $23.83M
YoY Change -5.44% 2.69% 27.45%
Operating Profit -$17.25M -$18.08M -$23.83M
YoY Change -5.44% 2.69%
Interest Expense $1.190M $812.0K $884.0K
YoY Change 45.48% 19.06% -26.94%
% of Operating Profit
Other Income/Expense, Net $470.0K
YoY Change
Pretax Income -$16.06M -$17.27M -$22.95M
YoY Change -7.83% 2.03% 31.22%
Income Tax
% Of Pretax Income
Net Earnings -$16.06M -$17.27M -$22.95M
YoY Change -7.83% 2.03% 31.22%
Net Earnings / Revenue
Basic Earnings Per Share -$0.27 -$0.29 -$0.39
Diluted Earnings Per Share -$0.27 -$0.29 -$390.3K
COMMON SHARES
Basic Shares Outstanding 58.89M 58.82M 58.80M
Diluted Shares Outstanding 59.27M 58.82M 58.80M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $128.3M $139.4M $156.6M
YoY Change -33.4% -32.91% 18.37%
Cash & Equivalents $59.03M $54.83M $71.77M
Short-Term Investments $69.26M $84.59M $84.84M
Other Short-Term Assets $3.813M $2.617M $3.635M
YoY Change -1.19% 9.91% 29.82%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $132.1M $142.0M $160.2M
YoY Change -32.77% -32.42% 18.61%
LONG-TERM ASSETS
Property, Plant & Equipment $6.316M $6.629M $32.37M
YoY Change -20.86% -21.2% 320.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.780M $1.780M $1.780M
YoY Change 0.0% 0.0% -1.11%
Total Long-Term Assets $32.03M $33.08M $34.15M
YoY Change 228.1% 224.56% 259.43%
TOTAL ASSETS
Total Short-Term Assets $132.1M $142.0M $160.2M
Total Long-Term Assets $32.03M $33.08M $34.15M
Total Assets $164.1M $175.1M $194.4M
YoY Change -20.42% -20.54% 34.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.578M $2.047M $4.438M
YoY Change 36.69% -30.21% 111.33%
Accrued Expenses $6.722M $5.786M $9.655M
YoY Change -12.77% -23.82% 48.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.92M $11.26M $14.09M
YoY Change 27.34% 1.56% 53.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $27.18M $28.19M $29.10M
YoY Change 324.57% 340.22% 354.75%
Total Long-Term Liabilities $27.18M $28.19M $29.10M
YoY Change 324.57% 340.22% 354.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.92M $11.26M $14.09M
Total Long-Term Liabilities $27.18M $28.19M $29.10M
Total Liabilities $40.10M $39.44M $43.20M
YoY Change 142.31% 125.57% 176.9%
SHAREHOLDERS EQUITY
Retained Earnings -$381.9M -$365.8M
YoY Change
Common Stock $506.3M $502.1M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $124.0M $135.7M $151.2M
YoY Change
Total Liabilities & Shareholders Equity $164.1M $175.1M $194.4M
YoY Change -20.42% -20.54% 34.43%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$16.06M -$17.27M -$22.95M
YoY Change -7.83% 2.03% 31.22%
Depreciation, Depletion And Amortization $471.0K $477.0K $511.0K
YoY Change -11.47% -1.24% 8.72%
Cash From Operating Activities -$13.81M -$16.85M -$19.74M
YoY Change -1.84% 29.6% 17.72%
INVESTING ACTIVITIES
Capital Expenditures -$158.0K -$129.0K -$27.00K
YoY Change -86.03% 19.44% 170.0%
Acquisitions
YoY Change
Other Investing Activities $15.40M $0.00 -$40.12M
YoY Change -12.01% -100.0% -634.89%
Cash From Investing Activities $15.24M -$129.0K -$40.14M
YoY Change -6.89% -100.43% -635.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.763M 49.00K 0.000
YoY Change 1261.08% -99.94% -100.0%
NET CHANGE
Cash From Operating Activities -13.81M -16.85M -19.74M
Cash From Investing Activities 15.24M -129.0K -40.14M
Cash From Financing Activities 2.763M 49.00K 0.000
Net Change In Cash 4.196M -16.93M -59.89M
YoY Change 67.5% -116.01% 575.9%
FREE CASH FLOW
Cash From Operating Activities -$13.81M -$16.85M -$19.74M
Capital Expenditures -$158.0K -$129.0K -$27.00K
Free Cash Flow -$13.65M -$16.72M -$19.71M
YoY Change 5.52% 29.68% 17.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2015-06-01
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001690585
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38541
dei Entity Registrant Name
EntityRegistrantName
Magenta Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-0724163
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Technology Square
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
242-0170
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
131650000
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
MGTA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58890486
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54832000
CY2022Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
84593000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
45276000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2617000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3767000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
142042000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
180693000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1780000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1780000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24670000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6629000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7461000
CY2022Q2 us-gaap Assets
Assets
175121000
CY2021Q4 us-gaap Assets
Assets
189934000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2047000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3040000
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5786000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
7823000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3423000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11256000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10863000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28187000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2022Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
0
CY2021Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
6399000
CY2022Q2 us-gaap Liabilities
Liabilities
39443000
CY2021Q4 us-gaap Liabilities
Liabilities
17262000
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58848861
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58848861
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58799157
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58799157
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
59000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
59000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
502009000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
498210000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-602000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-30000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-365788000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-325567000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
135678000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
172672000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
175121000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
189934000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11603000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11129000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28150000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22857000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6480000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6481000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13767000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13450000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
18083000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
17610000
us-gaap Operating Expenses
OperatingExpenses
41917000
us-gaap Operating Expenses
OperatingExpenses
36307000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18083000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17610000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41917000
us-gaap Operating Income Loss
OperatingIncomeLoss
-36307000
CY2022Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
812000
CY2021Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
682000
us-gaap Interest And Other Income
InterestAndOtherIncome
1696000
us-gaap Interest And Other Income
InterestAndOtherIncome
1890000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17271000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16928000
us-gaap Net Income Loss
NetIncomeLoss
-40221000
us-gaap Net Income Loss
NetIncomeLoss
-34417000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3750000
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58815543
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58815543
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53705289
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53705289
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58807395
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58807395
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51150391
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51150391
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17271000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16928000
us-gaap Net Income Loss
NetIncomeLoss
-40221000
us-gaap Net Income Loss
NetIncomeLoss
-34417000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-133000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-572000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
25000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-133000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-7000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-572000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
25000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17404000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16935000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40793000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34392000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
151188000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
49000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1845000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-133000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17271000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
135678000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
129059000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2451000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
86000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2134000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16928000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
202892000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
172672000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
49000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-572000
us-gaap Net Income Loss
NetIncomeLoss
-40221000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
135678000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
143906000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2869000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
86000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4326000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
25000
us-gaap Net Income Loss
NetIncomeLoss
-34417000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
202892000
us-gaap Profit Loss
ProfitLoss
-40221000
us-gaap Profit Loss
ProfitLoss
-34417000
us-gaap Share Based Compensation
ShareBasedCompensation
3750000
us-gaap Share Based Compensation
ShareBasedCompensation
4326000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
988000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
953000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-90000
mgta Noncash Lease Expense
NoncashLeaseExpense
1418000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-228000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-437000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1150000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-311000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-993000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1996000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1482000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
402000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1432000
us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-120000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36594000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29774000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
156000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
118000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
40117000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
37500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-40273000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
37382000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
86400000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
81000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2869000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
49000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
86000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
89274000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-76818000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
96882000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
133430000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
59932000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56612000
us-gaap Net Income Loss
NetIncomeLoss
-40200000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-71100000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
156814000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1025000
mgta Deferredofferingandredeemableconvertiblepreferred Share Issuance Cost Included In Accounts Payable Or Accrued Expenses
DeferredofferingandredeemableconvertiblepreferredShareIssuanceCostIncludedInAccountsPayableOrAccruedExpenses
-222000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q2 mgta Aggregate Value Of Securities Available Under The Shelf
AggregateValueOfSecuritiesAvailableUnderTheShelf
281000000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-365800000
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</div><br/></div>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8870622
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6637141
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
85195000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
602000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
84593000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
45306000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
30000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
45276000
CY2022Q2 mgta Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
2806000
CY2021Q4 mgta Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
2813000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2209000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3346000
CY2021Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
555000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
771000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1109000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5786000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7823000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1845000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2134000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3750000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4326000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
17500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
us-gaap Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
The Company has a sublease, as amended, for up to approximately 69,000 square feet of office and laboratory space in Cambridge, Massachusetts. The sublease is subject and subordinate to a prime lease between the sublandlord and the prime landlord. The term of the sublease commenced in June 2018 and expires in February 2028. The sublandlord has the right to terminate the sublease after five years.
mgta Sublease Commencement Period
SubleaseCommencementPeriod
2018-06
mgta Sublease Expiration Period
SubleaseExpirationPeriod
2028-02
mgta Sublease Termination Period
SubleaseTerminationPeriod
P5Y
CY2021Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
6400000
CY2021Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
600000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1601000
us-gaap Operating Lease Cost
OperatingLeaseCost
3203000
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
4000
us-gaap Variable Lease Cost
VariableLeaseCost
510000
CY2022Q2 us-gaap Lease Cost
LeaseCost
1605000
us-gaap Lease Cost
LeaseCost
3713000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2022Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
1622000
us-gaap Operating Lease Payments
OperatingLeasePayments
3217000
CY2022Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y8M1D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.11
CY2022Q2 mgta Lessee Operating Lease Liability Payment Due Six Months
LesseeOperatingLeaseLiabilityPaymentDueSixMonths
3350000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6936000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
7313000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
7679000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
8062000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
9904000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
43244000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11634000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
31610000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3423000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28187000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
31610000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
6375000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
6734000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
7100000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
7455000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
7828000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
9617000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
45109000
us-gaap Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage
DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
0.02

Files In Submission

Name View Source Status
0001193125-22-211881-index-headers.html Edgar Link pending
0001193125-22-211881-index.html Edgar Link pending
0001193125-22-211881.txt Edgar Link pending
0001193125-22-211881-xbrl.zip Edgar Link pending
d321742d10q.htm Edgar Link pending
d321742d10q_htm.xml Edgar Link completed
d321742dex311.htm Edgar Link pending
d321742dex312.htm Edgar Link pending
d321742dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mgta-20220630.xsd Edgar Link pending
mgta-20220630_cal.xml Edgar Link unprocessable
mgta-20220630_def.xml Edgar Link unprocessable
mgta-20220630_lab.xml Edgar Link unprocessable
mgta-20220630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending